Frontiers in Cardiovascular Medicine (Jun 2020)
Stereotactic Radiotherapy for the Management of Refractory Ventricular Tachycardia: Promise and Future Directions
- Raphael Jumeau,
- Raphael Jumeau,
- Mahmut Ozsahin,
- Juerg Schwitter,
- Olgun Elicin,
- Tobias Reichlin,
- Laurent Roten,
- Nicolaus Andratschke,
- Michael Mayinger,
- Ardan M. Saguner,
- Jan Steffel,
- Oliver Blanck,
- Marie-Catherine Vozenin,
- Raphael Moeckli,
- Michele Zeverino,
- Véronique Vallet,
- Claudia Herrera-Siklody,
- Patrizio Pascale,
- Jean Bourhis,
- Etienne Pruvot
Affiliations
- Raphael Jumeau
- Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Raphael Jumeau
- Multidisciplinary Cancer Care Service, Radiation Oncology Unit, Riviera-Chablais Hospital, Rennaz, Switzerland
- Mahmut Ozsahin
- Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Juerg Schwitter
- Heart and Vessel Department, Cardiac MR Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Olgun Elicin
- Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
- Tobias Reichlin
- Department of Cardiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
- Laurent Roten
- Department of Cardiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
- Nicolaus Andratschke
- Department of Radiation Oncology, University Hospital Zurich, Zürich, Switzerland
- Michael Mayinger
- Department of Radiation Oncology, University Hospital Zurich, Zürich, Switzerland
- Ardan M. Saguner
- Department of Cardiology, University Heart Center Zurich, Zürich, Switzerland
- Jan Steffel
- Department of Cardiology, University Heart Center Zurich, Zürich, Switzerland
- Oliver Blanck
- Department of Radiation Oncology and Department of Internal Medicine III, Cardiology, Section for Electrophysiology, University Medical Center Schleswig-Holstein, Kiel, Germany
- Marie-Catherine Vozenin
- Radio-Oncology Research Laboratory, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Raphael Moeckli
- 0Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Michele Zeverino
- 0Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Véronique Vallet
- 0Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Claudia Herrera-Siklody
- 1Heart and Vessel Department, Service of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Patrizio Pascale
- 1Heart and Vessel Department, Service of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Jean Bourhis
- Department of Radiation Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- Etienne Pruvot
- 1Heart and Vessel Department, Service of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
- DOI
- https://doi.org/10.3389/fcvm.2020.00108
- Journal volume & issue
-
Vol. 7
Abstract
Ventricular tachycardia (VT) caused by myocardial scaring bears a significant risk of mortality and morbidity. Antiarrhythmic drug therapy (AAD) and catheter ablation remain the cornerstone of VT management, but both treatments have limited efficacy and potential adverse effects. Stereotactic body radiotherapy (SBRT) is routinely used in oncology to treat non-invasively solid tumors with high precision and efficacy. Recently, this technology has been evaluated for the treatment of VT. This review presents the basic underlying principles, proof of concept, and main results of trials and case series that used SBRT for the treatment of VT refractory to AAD and catheter ablation.
Keywords